心房颤动抗栓治疗进展.pptVIP

* * 法林明显降低联合终点事件发生率（8.64% vs 13.0%， P0.05），相对危险下降36 %。 * * * * * * * * * * * * * * * * * * * * ACTIVE is a phase III, multicenter, multinational, parallel randomized controlled evaluation of clopidogrel plus ASA, with factorial evaluation of irbesartan, for the prevention of vascular events in patients with atrial fibrillation. Patients will be enrolled over 2 years and followed to common termination date (expected to be about 4 years after enrollment of the first patient). About 14,000 patients will be included in the ACTIVE W or ACTIVE A trials. Due to the partial factorial design, patients